CTLA4Ig treatment in patients with multiple sclerosis

Vissia Viglietta, Kévin Bourcier, Guy J. Buckle, Brian C. Healy, Howard L. Weiner, David A. Hafler, Svetlana Egorova, Charles R.G. Guttmann, J R Rusche, Samia J. Khoury

Neurology · 2008 · 101 citations · 32 references

Concepts

Abstract

<b>Background: </b> The modulation of costimulatory pathways represents an original therapeutic approach to regulate T cell–mediated autoimmune diseases by preventing or reducing autoantigen-driven T-cell activation in humans. Autoreactive CD4<sup>+</sup> T cells play a critical role in initiating the immune response leading to the chronic inflammation and demyelination characteristic of multiple sclerosis (MS). <b>Methods: </b> We used IV infusions of CTLA4Ig to block the CD28/B7 T-cell costimulatory pathway in a phase 1 dose-escalation study in MS. Sixteen patients with relapsing–remitting MS received a single CTLA4Ig infusion and were monitored for up to 3 months after treatment. In an extension study, four additional subjects received four doses of CTLA4Ig. <b>Results: </b> CTLA4Ig was well tolerated in patients with MS, and most adverse events were rated as mild. Immunologic assessment of the patients showed a reduction in myelin basic protein (MBP) proliferation within 2 months of infusion and decreased interferon-γ production by MBP-specific lines. <b>Conclusions: </b> Inhibiting costimulatory molecule interactions by using CTLA4Ig seems safe in multiple sclerosis (MS), and the immunologic effects suggest that it may be a promising approach to regulate the inflammatory process associated with MS. <b>GLOSSARY: </b><b>1M</b> = 1 month after infusion; <b>2M</b> = 2 months after infusion; <b>3M</b> = 3 months after infusion; <b>8D</b> = 8 days after infusion; <b>AE</b> = adverse event; <b>AI</b> = Ambulation Index; <b>APC</b> = antigen-presenting cell; <b>BL</b> = baseline; <b>BL2</b> = second baseline; <b>BPF</b> = brain parenchymal fraction; <b>CTLA-4</b> = cytotoxic T lymphocyte–associated gene 4; <b>EDSS</b> = Expanded Disability Status Scale; <b>FDA</b> = Food and Drug Administration; <b>Gd</b>+ = gadolinium-enhanced; <b>hMBP</b> = human myelin basic protein; <b>IDO</b> = indolamine 2,3-dioxygenase; <b>IFN</b> = interferon; <b>IL</b> = interleukin; <b>MBP</b> = myelin basic protein; <b>MS</b> = multiple sclerosis; <b>MSFC</b> = Multiple Sclerosis Functional Composite; <b>PBMC</b> = peripheral blood mononuclear cell; <b>RA</b> = rheumatoid arthritis; <b>TE</b> = echo time; <b>TR</b> = repetition time; <b>URI</b> = upper respiratory infection; <b>UTI</b> = urinary tract infection; <b>WBC</b> = white blood cell.

References

32